HRP20231650T1 - Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka - Google Patents
Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka Download PDFInfo
- Publication number
- HRP20231650T1 HRP20231650T1 HRP20231650TT HRP20231650T HRP20231650T1 HR P20231650 T1 HRP20231650 T1 HR P20231650T1 HR P20231650T T HRP20231650T T HR P20231650TT HR P20231650 T HRP20231650 T HR P20231650T HR P20231650 T1 HRP20231650 T1 HR P20231650T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- immune checkpoint
- checkpoint inhibitor
- sequence
- cocktail
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims 30
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title claims 30
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title claims 30
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims 30
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 3
- 229960005486 vaccine Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims 43
- 239000012634 fragment Substances 0.000 claims 32
- 230000002163 immunogen Effects 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 12
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172760 | 2016-06-02 | ||
| PCT/EP2017/063589 WO2017207814A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| EP17729078.0A EP3463436B1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231650T1 true HRP20231650T1 (hr) | 2024-05-10 |
Family
ID=56132759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231650TT HRP20231650T1 (hr) | 2016-06-02 | 2017-06-02 | Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11419927B2 (enExample) |
| EP (2) | EP4253419A3 (enExample) |
| JP (2) | JP7321709B2 (enExample) |
| AU (1) | AU2017275782B2 (enExample) |
| CA (1) | CA3026172A1 (enExample) |
| DK (1) | DK3463436T3 (enExample) |
| ES (1) | ES2965957T3 (enExample) |
| FI (1) | FI3463436T3 (enExample) |
| HR (1) | HRP20231650T1 (enExample) |
| HU (1) | HUE065176T2 (enExample) |
| LT (1) | LT3463436T (enExample) |
| PL (1) | PL3463436T3 (enExample) |
| PT (1) | PT3463436T (enExample) |
| RS (1) | RS65007B1 (enExample) |
| SI (1) | SI3463436T1 (enExample) |
| WO (1) | WO2017207814A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108383894A (zh) | 2010-02-16 | 2018-08-10 | 阿尔特公司 | 多肽及其应用 |
| EP4253419A3 (en) | 2016-06-02 | 2024-05-22 | Ultimovacs ASA | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| GB201803178D0 (en) | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| EP3815711A4 (en) * | 2018-06-29 | 2022-08-10 | Taiho Pharmaceutical Co., Ltd. | ANTITUMOR AGENT AND ITS METHOD OF EVALUATION |
| JP2024522178A (ja) | 2021-06-09 | 2024-06-11 | ウルティモバックス アクチボラグ | コンジュゲート |
| WO2024083867A1 (en) * | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Biomarker |
| WO2024126737A1 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A core and a conjugate |
| WO2024126758A2 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A nucleic acid molecule and a chimeric polypeptide |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE353365T1 (de) | 1999-08-23 | 2007-02-15 | Dana Farber Cancer Inst Inc | Neue b7-4 moleküle und deren verwendungen |
| CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| PT1503794E (pt) | 2002-04-12 | 2012-06-21 | Medarex Inc | Métodos de tratamento usando anticorpos contra ctla-4 |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| PL1907424T3 (pl) | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| RU2017132160A (ru) | 2008-12-09 | 2019-02-08 | Дженентек, Инк. | Антитела к pd-l1 и их применение для усиления функции t-клеток |
| CN108383894A (zh) | 2010-02-16 | 2018-08-10 | 阿尔特公司 | 多肽及其应用 |
| HRP20170251T1 (hr) | 2010-03-15 | 2017-04-21 | Stichting Voor De Technische Wetenschappen | Peptidi, konjugati i postupak za povećanje imunogenosti cjepiva |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| AU2013308409A1 (en) | 2012-08-31 | 2015-03-26 | University Of Birmingham | Target peptides for immunotherapy and diagnostics |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| ES2739913T3 (es) * | 2013-02-22 | 2020-02-04 | Curevac Ag | Combinación de vacunación e inhibición de la ruta PD-1 |
| EA034110B1 (ru) | 2013-03-15 | 2019-12-27 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Противораковые вакцины и способы лечения с их применением |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| JP2017500313A (ja) | 2013-12-09 | 2017-01-05 | ブレット バイオテクノロジー， インコーポレーテッドＢｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 特異的ウイルス様粒子−ＣｐＧオリゴヌクレオチドワクチンおよびその使用 |
| BR112016014410A2 (pt) | 2013-12-20 | 2018-02-20 | The Broad Institute Inc. | terapia de combinação com vacina de neoantígeno |
| EP3088614B1 (en) | 2013-12-27 | 2021-08-25 | Xiamen Solex High-Tech Industries Co., Ltd. | Flush-mounted pre-embedded assembly |
| SG11201606625RA (en) | 2014-02-14 | 2016-09-29 | Immune Design Corp | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| WO2015128313A1 (en) | 2014-02-25 | 2015-09-03 | Deutsches Krebsforschungszentrum | Rna viruses for immunovirotherapy |
| CA2946418C (en) | 2014-05-13 | 2023-07-04 | Bavarian Nordic A/S | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| DK3142689T3 (da) | 2014-05-13 | 2021-02-15 | Bavarian Nordic As | Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3 |
| EP3164157A4 (en) | 2014-07-01 | 2018-02-28 | Vicus Therapeutics, LLC | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| WO2016007504A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| CA2954278A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| MX2017000836A (es) | 2014-07-18 | 2017-11-17 | Advaxis Inc | Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. |
| US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| US20190282632A1 (en) | 2014-10-23 | 2019-09-19 | Institut Gustave Roussy | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| WO2016073759A1 (en) | 2014-11-05 | 2016-05-12 | The Regents Of The University Of California | Combination immunotherapy |
| WO2017125844A1 (en) | 2016-01-19 | 2017-07-27 | Pfizer Inc. | Cancer vaccines |
| EP4253419A3 (en) | 2016-06-02 | 2024-05-22 | Ultimovacs ASA | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
-
2017
- 2017-06-02 EP EP23178501.5A patent/EP4253419A3/en active Pending
- 2017-06-02 US US16/306,352 patent/US11419927B2/en active Active
- 2017-06-02 EP EP17729078.0A patent/EP3463436B1/en active Active
- 2017-06-02 DK DK17729078.0T patent/DK3463436T3/da active
- 2017-06-02 PL PL17729078.0T patent/PL3463436T3/pl unknown
- 2017-06-02 FI FIEP17729078.0T patent/FI3463436T3/fi active
- 2017-06-02 PT PT177290780T patent/PT3463436T/pt unknown
- 2017-06-02 HR HRP20231650TT patent/HRP20231650T1/hr unknown
- 2017-06-02 WO PCT/EP2017/063589 patent/WO2017207814A1/en not_active Ceased
- 2017-06-02 HU HUE17729078A patent/HUE065176T2/hu unknown
- 2017-06-02 AU AU2017275782A patent/AU2017275782B2/en not_active Ceased
- 2017-06-02 LT LTEPPCT/EP2017/063589T patent/LT3463436T/lt unknown
- 2017-06-02 RS RS20231231A patent/RS65007B1/sr unknown
- 2017-06-02 ES ES17729078T patent/ES2965957T3/es active Active
- 2017-06-02 JP JP2018563076A patent/JP7321709B2/ja active Active
- 2017-06-02 CA CA3026172A patent/CA3026172A1/en active Pending
- 2017-06-02 SI SI201731461T patent/SI3463436T1/sl unknown
-
2022
- 2022-08-09 US US17/818,584 patent/US12168045B2/en active Active
- 2022-08-24 JP JP2022132995A patent/JP2022171684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017207814A1 (en) | 2017-12-07 |
| PL3463436T3 (pl) | 2024-03-04 |
| LT3463436T (lt) | 2024-01-25 |
| PT3463436T (pt) | 2023-12-28 |
| DK3463436T3 (da) | 2023-12-18 |
| ES2965957T3 (es) | 2024-04-17 |
| AU2017275782B2 (en) | 2024-08-15 |
| CA3026172A1 (en) | 2017-12-07 |
| JP2019517508A (ja) | 2019-06-24 |
| RS65007B1 (sr) | 2024-01-31 |
| SI3463436T1 (sl) | 2024-02-29 |
| US20230049012A1 (en) | 2023-02-16 |
| EP3463436B1 (en) | 2023-09-20 |
| US12168045B2 (en) | 2024-12-17 |
| HUE065176T2 (hu) | 2024-05-28 |
| JP7321709B2 (ja) | 2023-08-07 |
| JP2022171684A (ja) | 2022-11-11 |
| US20190247482A1 (en) | 2019-08-15 |
| US11419927B2 (en) | 2022-08-23 |
| AU2017275782A1 (en) | 2019-01-24 |
| EP3463436A1 (en) | 2019-04-10 |
| FI3463436T3 (fi) | 2023-12-04 |
| EP4253419A3 (en) | 2024-05-22 |
| EP4253419A2 (en) | 2023-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231650T1 (hr) | Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| BR112017003194A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, vacina, vaso ou dispositivo de injeção, e, métodos para antagonizar lag3 em um paciente humano que necessita do mesmo, para tratamento de um câncer em um indivíduo para administrar o anticorpo, o fragmento, a composição, o polipeptídeo, a vacina, o vetor ou o polinucleotídeo de ligação ao antígeno a um indivíduo, para produção de um anticorpo ou de um fragmento de ligação ao antígeno do mesmo ou polipeptídeo e para detectar a presença de um peptídeo lag3 ou de um fragmento do mesmo em uma amostra. | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| EA202190669A1 (ru) | Процесс получения вакцинной композиции | |
| JP2018501197A5 (enExample) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
| HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
| MX2019006349A (es) | Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas. | |
| CO2020012621A2 (es) | Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso | |
| BR112019008351A2 (pt) | imunoglobulinas e usos das mesmas | |
| JP2016527286A5 (enExample) | ||
| JP2019514998A5 (enExample) | ||
| SI3079715T1 (en) | A mixture of peptides | |
| HRP20212034T1 (hr) | Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| JP2019517508A5 (enExample) | ||
| MX2023008115A (es) | Terapia con receptores quiméricos. | |
| CL2020003292A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| HRP20210207T1 (hr) | Uporaba protutijela anti-sklerostin u liječenju osteogenesis imperfecta | |
| BR112019011350A2 (pt) | terapia de combinação |